Under the partnership InstrAction will screen its 3,000 strong library of stationary-phase API selective resins for the best candidates for taxane separation, which Novasep will then use to develop production processes.
The aim is to develop simplified taxane purification processes according to Novasep spokesman Jean Blehaut, who told in-PharmaTechnologist.com about some of the benefits the approach has already demonstrated.
“For one generic taxane overall process productivity was increased by a 15-fold factor,” Blehaut explained, adding that recovery yields using the instrAction phases were around 90 per cent, compared with 36 per cent for traditional media.
The deal expands on the API purification collaboration the firms established in July last year, and according to Blehaut, is a testament to that accord’s success and growing market demand for cost-efficient processing.
“APIs in general are becoming more and more complex, driven by the need by pharmaceutical companies for developing innovative drug candidates as well as by the development of more targeted therapies.
“More complex molecules are more difficult to synthesize, and an increasing number of API manufacturing processes requires advanced purification technologies.”
This was echoed by InstrAction spokesman Bjoern Degel, who told in-Pharmatechnologist.com that: “The area of taxanes is a very interesting and attractive business field where we wanted to demonstrate the efficacy of the alliance for API purification.”